Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004–2007)

This publication has 21 references indexed in Scilit:

• A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae
  Journal of Antimicrobial Chemotherapy, 2008
• Evolving problems with resistant pathogens
  Clinical Microbiology & Infection, 2008
• Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial
  Clinical Microbiology & Infection, 2008
• Strategies for managing today's infections
  Clinical Microbiology & Infection, 2008
• Metallo beta lactamases inPseudomonas aeruginosaand Acinetobacter species
  Expert Opinion on Investigational Drugs, 2008
• Prevalence and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae in Europe
  Clinical Microbiology & Infection, 2008
• Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000–2004)
  Diagnostic Microbiology and Infectious Disease, 2005
• Antimicrobial resistance of Acinetobacter spp. in Europe
  Clinical Microbiology & Infection, 2004
• In Vitro Susceptibilities of Gram-Negative Bacteria Isolated from Hospitalized Patients in Four European Countries, Canada, and the United States in 2000-2001 to Expanded-Spectrum Cephalosporins and Comparator Antimicrobials: Implications for Therapy
  Antimicrobial Agents and Chemotherapy, 2003
• The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997–2000
  Clinical Microbiology & Infection, 2003